Jefferies has initiated coverage on Moderna Inc (MRNA) with a Hold rating as of December 11, 2025. This marks the firm's first assessment of the biotechnology company, which focuses on developing transformative medicines based on messenger ribonucleic acid (mRNA).
Moderna, headquartered in Cambridge, Massachusetts, has a market capitalization of $11.3 billion and employs 5,800 full-time staff. The company is advancing a diverse pipeline of 44 therapeutic and vaccine programs, including 11 in late-stage development. Its commercial offerings encompass Spikevax, a COVID-19 vaccine, and mRESVIA, a vaccine for respiratory syncytial virus (RSV).
As of now, the stock price stands at $29.82. Analyst consensus indicates a Hold rating, with 0 Strong Buy, 4 Buy, 18 Hold, 4 Sell, and 3 Strong Sell ratings among 29 analysts. Upcoming earnings reports are scheduled for April 29, 2026, with an estimated EPS of $-2.40 and revenue of $218.2 million, and July 30, 2026, with an estimated EPS of $-2.37 and revenue of $117.6 million.
The announcement highlights that analyst ratings can evolve as new data emerges, and they should be considered alongside other factors such as company fundamentals and market conditions.